InvestorsHub Logo

DewDiligence

10/20/16 9:01 AM

#205364 RE: DewDiligence #204335

RIGL -34%/PM on phase-3 failure of Fostamatinib in ITP:

http://finance.yahoo.com/news/rigel-announces-results-second-fit-110000528.html